Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

doi:10.1111/bjh.19459

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).

British journal of haematology - 1 Aug 2024

Nguyen-Khac Florence, Baron Marine, Guièze Romain, Feugier Pierre, Fayault Alexandra, Raynaud Sophie, Troussard Xavier, Droin Nathalie, Damm Frederik, Smagghe Luce, Susin Santos, Leblond Véronique, Dartigeas Caroline, Van den Neste Eric, Leprêtre Stéphane, Bernard Olivier A, Roos-Weil Damien

Abstract excerpt

The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative analysis on genetic abnormalities identified through cytogenetics and targeted next-generation sequencing in 536 CLL patients receiving first-line chemo(immuno)therapies (CIT) as part of two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Deletion

Share to Chromosomes, Human, Pair 17

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Immunotherapy

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 38654616
DOI: 10.1111/bjh.19459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).PMID 38654616Read ↗

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapySemantic proximity Read ↗

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.Semantic proximity Read ↗

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity Read ↗

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.Semantic proximity Read ↗

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.Semantic proximity Read ↗

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.Semantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.Semantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.